Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MDS 2021 | MDS: managing HMA failure

Valeria Santini • 25 Jan 2021
ESH MDS 2021
Myelodysplastic Syndromes Antibodies Azacitidine Decitabine Magrolimab Venetoclax

Hypomethylating agents (HMA), such as azacitidine and decitabine are standard of care for myelodysplastic syndromes (MDS). However, there remain few options for patients who fail HMAs, which indeed a great many do. Valeria Santini, MD, University of Florence, Florence, Italy, discusses rescue strategies for this patient population. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.

More from Valeria Santini

2:57
Imetelstat for LR-MDS: insights from the IMerge trial
Valeria Santini • 11 Dec 2023
2:52
Long-term evaluation of luspatercept in ESA-intolerant/refractory LR-MDS: MEDALIST follow-up study
Valeria Santini • 11 Dec 2023
1:34
Managing adverse events with novel therapies in lower-risk MDS
Valeria Santini • 7 Sep 2023
2:25
Approaching ESA failure in patients with lower-risk MDS
Valeria Santini • 7 Sep 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals